Epidemiology of psychiatric disorders in Edmonton. Major depressive disorder
- PMID: 8178688
Epidemiology of psychiatric disorders in Edmonton. Major depressive disorder
Abstract
A random sample of 3258 adult household residents of Edmonton, Alberta, Canada, were interviewed by trained lay interviewers, using the Diagnostic Interview Schedule (DIS), which generated DSM-III diagnosis data. This paper reports results for major depressive disorder (MDD). MDD was found to affect women more than men by a ratio of nearly 2 to 1. The lifetime prevalence rate for both sexes combined was 8.6%. The period prevalence rates for both sexes combined were 3.2% and 4.6%, for six month and one year, respectively. The presence of a recurrent Major Depressive Disorder was associated with an increased risk of substance abuse, panic disorder and dysthymia, whereas a single major depressive episode was not associated with increased comorbidity.
Similar articles
-
Epidemiology of psychiatric disorders in Edmonton. Panic disorder.Acta Psychiatr Scand Suppl. 1994;376:45-53. Acta Psychiatr Scand Suppl. 1994. PMID: 8178684
-
Epidemiology of psychiatric disorders in Edmonton. Phobic disorders.Acta Psychiatr Scand Suppl. 1994;376:36-44. Acta Psychiatr Scand Suppl. 1994. PMID: 8178683
-
Epidemiology of psychiatric disorders in Edmonton. Obsessive-compulsive disorder.Acta Psychiatr Scand Suppl. 1994;376:24-35. Acta Psychiatr Scand Suppl. 1994. PMID: 8178682
-
The impact of criteria selection on prevalence rates.Psychiatr J Univ Ott. 1990 Nov;15(4):194-9. Psychiatr J Univ Ott. 1990. PMID: 2284370 Review.
-
[Dysthymic disorders. Clinical aspects, nosology and epidemiology].Encephale. 1992 Dec;18 Spec No 5:707-15. Encephale. 1992. PMID: 1342670 Review. French. No abstract available.
Cited by
-
Sertraline. A pharmacoeconomic evaluation of its use in depression.Pharmacoeconomics. 1996 Oct;10(4):409-31. doi: 10.2165/00019053-199610040-00009. Pharmacoeconomics. 1996. PMID: 10184609 Review.
-
Paroxetine. A pharmacoeconomic evaluation of its use in depression.Pharmacoeconomics. 1995 Jul;8(1):62-81. doi: 10.2165/00019053-199508010-00008. Pharmacoeconomics. 1995. PMID: 10155603 Review.
-
Exercise therapy improves aerobic capacity of inpatients with major depressive disorder.Brain Behav. 2016 Apr 22;6(6):e00469. doi: 10.1002/brb3.469. eCollection 2016 Jun. Brain Behav. 2016. PMID: 27134769 Free PMC article.
-
Predisposition locus for major depression at chromosome 12q22-12q23.2.Am J Hum Genet. 2003 Dec;73(6):1271-81. doi: 10.1086/379978. Epub 2003 Nov 5. Am J Hum Genet. 2003. PMID: 14606042 Free PMC article.
-
Fluoxetine. A pharmacoeconomic review of its use in depression.Pharmacoeconomics. 1998 May;13(5 Pt 1):543-61. doi: 10.2165/00019053-199813050-00007. Pharmacoeconomics. 1998. PMID: 10180753 Review.